Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial (2018)

Peer-Reviewed Study · Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, Storey JMD, Harrington CR, Wischik CM · 2018

Wilcock GK et al., 2018: The disputed re-analysis: the sponsor changed the primary analysis of the failed mild-AD trial before unblinding so that non-randomised monotherapy cohort comparisons became the primary outcomes, and reported significant benefits, including at the 4 mg 'placebo' dose.

As the originally intended analysis was unlikely to achieve its intended purpose, we modified the primary analyses and treatment comparisons in the TRx-237-005 Statistical Analysis Plan prior to database lock and unblinding

Methods, 'Statistical analysis'

Wilcock GK et al., 2018: The disputed re-analysis: the sponsor changed the primary analysis of the failed mild-AD trial before unblinding so that non-randomised monotherapy cohort comparisons became the primary outcomes, and reported significant benefits, including at the 4 mg 'placebo' dose. This row records the sponsor's position at full strength and is the core of the dispute. Study type: post-hoc/cohort re-analysis of a randomised phase 3 (NCT01689233, n=800). Comparator: non-randomised cohorts (100 mg BID monotherapy, n=79, vs 4 mg BID as randomised, n=396; 4 mg BID monotherapy, n=76, vs 4 mg BID add-on, n=297). Country: 108 sites, Canada/US/Australia/Europe. Funder: TauRx, which 'took the lead in study design, undertaking the study, data interpretation, and initial drafting'. Results claimed: ADAS-cog effect -3.14 (95% CI -5.32 to -0.97, p=0.0047) and ADCS-ADL 3.49 (0.66 to 6.30, p=0.0157). The paper itself states 'There was no evidence of any difference on any of the primary or secondary endpoints in the as-randomized analyses defined in the protocol.' Critique: MTC-085, MTC-084. Also filed as MTC-041 (claims C6, F1). Study type: controlled study.